The Political Economy of HIV/AIDS in Developing Countries
Show Less

The Political Economy of HIV/AIDS in Developing Countries

TRIPS, Public Health Systems and Free Access

Edited by Benjamin Coriat

The book is based on original data and field studies from Brazil, Thailand, India and Sub-Saharan Africa. Focusing on the issue of universal and free access to treatment (a goal now taken to heart by the international community), it assesses the progress made and presents a rigorous diagnosis of the obstacles that remain, especially the constraints imposed by TRIPS and the poor state of most public health systems in Southern countries. In so doing, the book renews our understanding of the political economy of HIV/AIDS in these vast regions, where it continues to spread with devastating social and economic consequences.
Show Summary Details
You do not have access to this content

Chapter 3: Evolution of Prices and Quantities for ARV Drugs in African Countries: From Emerging to Strategic Markets

Julien Chauveau, Constance Marie Meiners, Stéphane Luchini and Jean Paul Moatti


3. Evolution of prices and quantities of ARV drugs in African countries: from emerging to strategic markets Julien Chauveau, Constance Marie Meiners, Stéphane Luchini and Jean-Paul Moatti INTRODUCTION Access to antiretroviral therapies (ART) in the developing world has made significant progress over recent years. The World Health Organization (WHO) reported that treatment coverage increased more than threefold in three years, benefiting more than 1.3 million patients at the end of 2005. The spread of ART was of particular importance in Sub-Saharan Africa, the most severely stricken region in the world, where more than half of the people under treatment in the developing world are currently living (WHO/UNAIDS, 2006). Bolstered by such progress, the fight against the HIV/AIDS epidemic moved into a new phase in June 2006, with the commitment from United Nations member states, during the General Assembly High Level Meeting on AIDS, to work toward the goal of ‘universal access to comprehensive prevention programmes, treatment, care and support’ by 2010 (WHO, 2006a). The desirable, yet ambitious, goal of achieving universal access still faces the challenge of its implementation. Optimism that can be legitimately drawn from concrete advances made in Sub-Saharan African countries has to be weighed against the fact that only 17 per cent of patients who needed them had access to multi-therapies in 2005 (WHO/UNAIDS, 2006). Beyond the need to accelerate access to HIV/AIDS treatments, a broader ART coverage raises the issue of programme continuity and sustainability. Treatment costs are a major challenge to be...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.